Home » Stocks » AMED

Amedisys Inc. (AMED)

Stock Price: $282.96 USD -1.03 (-0.36%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 9.29B
Revenue (ttm) 2.07B
Net Income (ttm) 183.61M
Shares Out 32.56M
EPS (ttm) 5.52
PE Ratio 51.26
Forward PE 44.84
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $282.96
Previous Close $283.99
Change ($) -1.03
Change (%) -0.36%
Day's Open 285.41
Day's Range 281.54 - 288.21
Day's Volume 163,691
52-Week Range 165.42 - 325.12

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Amedisys' (AMED) new agreement to acquire Randolph Country regulatory assets will broaden the company's footprint in the Home Health care market.

3 days ago - Zacks Investment Research

BATON ROUGE, La., April 14, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, will report results for the first quarter ended March 31...

4 days ago - GlobeNewsWire

BATON ROUGE, La., April 14, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice and personal care, has signed a definitive agreement to acquire reg...

4 days ago - GlobeNewsWire

Biden's support to expand access to long-term care services under Medicaid bodes well for companies providing home healthcare.

Other stocks mentioned: ADUS, LHCG
2 weeks ago - Zacks Investment Research

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

BATON ROUGE, La., March 01, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Chie...

1 month ago - GlobeNewsWire

Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.

1 month ago - Zacks Investment Research

Shares of Amedisys (NASDAQ:AMED) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 58.51% over the past year to $1.49, which beat th...

1 month ago - Benzinga

Christopher Gerard named President and Chief Operating Officer and Scott Ginn named Executive Vice President and Chief Financial Officer

1 month ago - GlobeNewsWire

On Wednesday, February 24, Amedisys (NASDAQ:AMED) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

1 month ago - Benzinga

Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 months ago - Zacks Investment Research

BATON ROUGE, La., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the fourth quarter and year ended December 31, 2020, after the market c...

2 months ago - GlobeNewsWire

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Some medical stocks gained momentum because of the pandemic, while others focus on high-reward challenges like cancer treatment. The post 7 Healthy Medical Stocks to Buy appeared first on InvestorPlace.

Other stocks mentioned: CRDF, FLGT, GHSI, NTRA, OMI, TDOC
2 months ago - InvestorPlace

Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.

Other stocks mentioned: MDRX, PKI
2 months ago - Zacks Investment Research

Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.

3 months ago - Zacks Investment Research

BATON ROUGE, La., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Presi...

3 months ago - GlobeNewsWire

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

BATON ROUGE, La., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America's leading independent home health, hospice and personal care company, today announced that its Board of Directo...

3 months ago - GlobeNewsWire

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

BATON ROUGE, La., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Presi...

5 months ago - GlobeNewsWire

Amedisys (AMED) continues to benefit from the recent acquisitions of hospice care providers.

5 months ago - Zacks Investment Research

BATON ROUGE, La., Nov. 10, 2020 (GLOBE NEWSWIRE) --  Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Pres...

5 months ago - GlobeNewsWire

BATON ROUGE, La., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Presi...

5 months ago - GlobeNewsWire

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.

5 months ago - Zacks Investment Research

An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.

5 months ago - Zacks Investment Research

Amedisys, Inc.'s (AMED) CEO Paul Kusserow on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

After a 82% rise since the March 16 lows of this year, at the current price of around $249 per share we believe Amedisys stock, a home health and hospice care company, has reached its near-term potentia...

5 months ago - Forbes

Amedisys (AMED) delivered earnings and revenue surprises of 76.38% and 2.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Amedisys (NASDAQ:AMED) fell 2.7% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 94.78% year over year to $2.24, which beat the estimat...

5 months ago - Benzinga

BATON ROUGE, La., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2020.

5 months ago - GlobeNewsWire

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Meritage Homes (MTH), Vertex Pharmaceuticals (VRTX), CVS Health (CVS)...

Other stocks mentioned: CVS, MTH, NSP, VRTX
5 months ago - Zacks Investment Research

BATON ROUGE, La., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the third quarter ended September 30, 2020, after the market closes on ...

6 months ago - GlobeNewsWire

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

BATON ROUGE, La., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Pre...

7 months ago - GlobeNewsWire

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.

7 months ago - Zacks Investment Research

BATON ROUGE, La., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, has signed a Care Coordination Agreemen...

7 months ago - GlobeNewsWire

Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.

8 months ago - Zacks Investment Research

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.

8 months ago - Zacks Investment Research

Shares of Amedisys (NASDAQ:AMED) were flat in after-market trading after the company reported Q2 results.

8 months ago - Benzinga

Amedisys (AMED) delivered earnings and revenue surprises of 69.62% and 4.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

BATON ROUGE, La., July 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month period ended June 30, 2020.

8 months ago - GlobeNewsWire

Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Amedisys is expected to report earnings on Jul. 28. Amedisys now trading 2% below the 218.54 buy point from a fourth-stage consolidation that it cleared earlier.

8 months ago - Investors Business Daily

About AMED

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its... [Read more...]

Industry
Medical Care Facilities
Founded
1982
CEO
Paul Kusserow
Employees
21,000
Stock Exchange
NASDAQ
Ticker Symbol
AMED
Full Company Profile

Financial Performance

In 2020, Amedisys's revenue was $2.07 billion, an increase of 5.93% compared to the previous year's $1.96 billion. Earnings were $183.61 million, an increase of 44.76%.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for Amedisys stock is "Buy." The 12-month stock price forecast is 327.33, which is an increase of 15.68% from the latest price.

Price Target
$327.33
(15.68% upside)
Analyst Consensus: Buy